Linus Health Highlights Innovations in Cognitive Assessment at CTAD 2026
Linus Health's Innovative Contributions at CTAD 2026
Today marks a significant milestone in dementia research as Linus Health presents its groundbreaking findings at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. This notable event runs from November 16 to 19, 2026, and serves as a premier global forum for advances in Alzheimer's disease clinical research. Linus Health, known for its AI-driven focus on brain health, is set to unveil six scientific posters that encompass the validation of digital cognitive assessments, predictions of amyloid status, and challenges in capturing patient-centered outcomes.
In the wake of growing statistics highlighting the impact of Alzheimer's, particularly the staggering 7.4 million Americans aged 65 and older diagnosed, research tools that can quickly and accurately identify individuals for eligibility in clinical trials are becoming increasingly critical. Linus Health's suite of technologies aims to meet this demand, making early identification and proactive intervention possible. David Bates, PhD, Co-Founder and CEO of Linus Health, emphasizes the importance of early detection, stating, “Alzheimer's research and routine clinical care increasingly depend on identifying cognitive change early.”
One of the highlights includes the Linus Cognitive Assess, formerly known as the Digital Clock and Recall (DCR), which integrates a digital clock-drawing test alongside word recall tasks. Early assessments indicated that this tool had a remarkable completion rate, demonstrating strong reliability and usability in a real-world setting with over 27,000 assessments conducted. The findings exhibit its potential as a cognitive screener in both primary care and clinical trial contexts.
Another key study explores the Linus Cognitive Profile, which employs speech-based assessments to examine memory and cognitive functioning. Initial findings suggest this tool can effectively predict patients' amyloid PET status, an essential aspect of determining the presence of Alzheimer’s pathology. Interestingly, the updated Radar model, which estimates dementia risk through analyzing health claims data via machine learning, indicated enhanced performance in differentiating patients with and without newly recorded dementia diagnoses, showcasing an area under the curve (AUC) of 0.831.
Linus Health's poster presentations also cover new findings on the electronic Person-Specific Outcome Measure (ePSOM) tool, showing its cultural applicability in Japanese memory clinics. Out of the 50 individuals participating, a staggering 80% acknowledged the relevance of the ePSOM assessment to their lives, underlining its potential value in diverse clinical settings.
With these advancements, Linus Health is not only reinforcing its commitment to early detection but also striving to align clinical trials and health systems with the growing demands of Alzheimer’s research. The extensive evidence supporting these digital tools positions Linus Health as a leader in transforming how cognitive impairment is identified and assessed in the medical field.
Larger trends in health systems also indicate a pivot toward integrated brain health programs. As these systems adapt to manage the expected influx of patients seeking new therapies, the role of robust and validated measurement tools like those from Linus Health cannot be overstated.
The conference offers an invaluable platform for Linus Health to engage with clinicians and trial sponsors, fostering collaboration that bridges the gap between research and practical application. Throughout the event, Linus scientists aim to provide insights into the operational use of these digital assessments and their application for trial recruitment, thereby enriching both clinical practice and research methodologies moving forward.
In summary, Linus Health's presence at CTAD 2026 represents a pivotal moment in advancing Alzheimer’s care. By harnessing digital solutions and innovative cognitive assessments, they are working towards not only improving clinical outcomes but also ensuring that the voices of patients remain central in the discussion of their health journeys.
For those interested in delving deeper into Linus Health's findings and the applications of their technologies, the company remains available for discussions and meetings throughout the CTAD conference dates.